Year: 2025

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Written by Customer Service on November 10, 2025. Posted in Public Companies.

BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Thursday, November 13, 2025 Time: 1:30pm ETWebcast: https://wsw.com/webcast/cowen185/vera/2021228 A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website. About Vera TherapeuticsVera Therapeutics is a late clinical-stage...

Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

Written by Customer Service on November 10, 2025. Posted in Public Companies.

JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) — ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio, enhancing Dyadic’s ability to accelerate strain engineering and pathway optimization to enhance productivity, product quality, and innovation across its proprietary bioproduction platforms. “Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s proprietary C1 and Dapibus production platforms,”...

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

Written by Customer Service on November 10, 2025. Posted in Public Companies.

– Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia and SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that analyses on the baseline characteristics related to orthostatic hypotension (OH) from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) were featured in an oral presentation at the American Autonomic Society (AAS) 36th International Symposium on the Autonomic Nervous System that took place in Clearwater Beach, Florida, USA. “As we...

Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History

Written by Customer Service on November 10, 2025. Posted in Earnings Releases And Operating Results.

Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 – $200M FY 2026 Revenue, $25M Monthly Revenue or $300M ARR by Year End 2026 IM8 Delivers 60% Gross Margin, 3.9 Months Payback Period, Demonstrating Strong Unit Economics Company to Host Earnings Call Today at 8:30am ET, Releases Inaugural Quarterly Shareholder Letter CHARLOTTE, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced third quarter 2025 financial results, highlighted by IM8’s trajectory towards $120 million in annualized recurring revenue (“ARR”) in just...

Galecto Announces Acquisition of Damora Therapeutics

Written by Customer Service on November 10, 2025. Posted in Mergers And Acquisitions.

Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms Damora Therapeutics, the sixth company launched based on assets developed by Paragon Therapeutics, is advancing a portfolio of anti-mutant calreticulin (mutCALR) targeted therapies, led by DMR-001, a potentially best-in-class monoclonal antibody targeting mutCALR Combined company with complementary assets expected to have financial runway into 2029 to support multiple data milestones, including Phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) — Galecto, Inc. (“Galecto”) today announced the completion of the acquisition of Damora Therapeutics, Inc. (“Damora”),...

Schouw & Co. share buy-back programme, week 45 2025

Written by Customer Service on November 10, 2025. Posted in Mergers And Acquisitions.

On 5 May 2025, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 20 of 2 May 2025. Under the programme, Schouw & Co. will acquire shares for up to DKK 120 million during the period 5 May to 31 December 2025. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount Accumulated until 31 October 2025 168,600 599.12 101,012,339 Monday, 3 November 2025 1,300 595.23 773,799 Tuesday, 4 November 2025 1,300 584.77 760,201 Wednesday, 5 November 2025 1,400 581.67 814,338 Thursday, 6 November 2025 1,400 579.00 810,600 Friday,...

Perma-Fix Reports Financial Results and Provides Business Update for the Third Quarter of 2025

Written by Customer Service on November 10, 2025. Posted in Earnings Releases And Operating Results.

ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Mark Duff, President and Chief Executive Officer (CEO) of the Company, commented, “We are pleased to report improved performance driven by a 45% year-over-year revenue increase and gross margin improvement in our Treatment Segment to 17.3% from 4.5% in the prior year. Higher waste volumes and growing international shipments contributed to improved results, and our treatment backlog continues to build, which we expect will lead to continued improvement through 2026. This growth spans both government and commercial waste streams, further diversifying our customer base and strengthening our overall operating...

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Written by Customer Service on November 10, 2025. Posted in Earnings Releases And Operating Results.

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over Year Nine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company’s Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available Cash Company Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Double-Digit Profitable Growth Interim Futility Analysis of the Pivotal Phase 3 InnovAATe Clinical Trial for the Inhaled AAT Therapy to be Conducted...

EVgo Inc. Reports Third Quarter 2025 Results

Written by Customer Service on November 10, 2025. Posted in Earnings Releases And Operating Results.

Total Revenues Increased 37% with Record Charging Network Revenue of $56 MillionTotal revenue of $92.3 million in the third quarter, representing an increase of 37% year-over-year. Charging network revenue totaled a record $55.8 million in the third quarter, an increase of 33% year-over-year, representing the 15th consecutive quarter of double-digit year-over-year charging revenue growth. Network throughput reached a record 95 gigawatt-hours (“GWh”) in the third quarter, an increase of 25% year-over-year. Added more than 280 new operational stalls during the third quarter. Ended the third quarter with 4,590 stalls in operation, an increase of 25% year-over-year. $201 million in cash, cash equivalents, and restricted cash. Additional borrowing of $41 million received in October.LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) — EVgo...

Bitdeer Reports Unaudited Financial Results for the Third Quarter of 2025

Written by Customer Service on November 10, 2025. Posted in Earnings Releases And Operating Results.

– $169.7 million revenue, up 173.6% year-over-year– $43.0 million adjusted EBITDA, up from negative $7.9 million last year– Expanding and accelerating AI strategy across multiple initiatives– Achieved 41.2 EH/s of self-mining at the end of October, 2025– Commenced SEALMINER A3 mass production– Early SEAL04 samples have demonstrated 6-7 J/TH power efficiency at the chip level under low-voltage, ultra-power saving mode SINGAPORE, Nov. 10, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for Bitcoin mining and AI cloud, today released its unaudited financial results for the third quarter ended September 30, 2025. Q3 2025 Financial HighlightsAll amounts compared to Q3 2024 unless otherwise notedTotal revenue was US$169.7...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals